NASDAQ · PTCT
Healthcare · Biotechnology
$60.99
Down-$1.44 (-2.36%)
Updated Oct 16, 2026, 7:29 PM
SID Score
4.8/10
Composite research score
Smart Money
58/100
Neutral
Price performance · PTCT
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 15, 2026
PTCT closed at $60.99 after 21 trading sessions, down 10.31% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 15, 2026 | $61.08 | $62.3099 | $59.88 | $60.99 | 1.05M |
| Oct 14, 2026 | $59.30 | $60.69 | $58.80 | $59.67 | 1.52M |
| Oct 13, 2026 | $62.64 | $62.75 | $59.82 | $59.92 | 1.05M |
| Oct 12, 2026 | $64.80 | $65.025 | $62.88 | $62.92 | 745.21K |
| Oct 9, 2026 | $62.52 | $64.73 | $62.20 | $64.70 | 1.17M |
| Oct 8, 2026 | $62.66 | $62.86 | $61.65 | $62.56 | 1.23M |
| Oct 7, 2026 | $63.19 | $64.04 | $62.84 | $63.23 | 1.04M |
| Oct 6, 2026 | $64.53 | $65.27 | $62.92 | $63.70 | 1.26M |
| Oct 5, 2026 | $63.42 | $64.47 | $62.60 | $63.65 | 1.04M |
| Oct 2, 2026 | $64.81 | $65.395 | $62.80 | $63.46 | 895.55K |
| Oct 1, 2026 | $64.70 | $65.565 | $63.40 | $64.13 | 1.2M |
| Sep 30, 2026 | $65.16 | $65.495 | $64.145 | $64.78 | 1.04M |
| Sep 29, 2026 | $65.51 | $65.965 | $64.265 | $64.96 | 900.44K |
| Sep 28, 2026 | $62.35 | $66.26 | $62.30 | $65.95 | 1.91M |
| Sep 25, 2026 | $62.65 | $63.435 | $61.66 | $62.67 | 1.2M |
| Sep 24, 2026 | $62.23 | $62.76 | $61.23 | $62.28 | 1.75M |
| Sep 23, 2026 | $65.80 | $66.1523 | $62.24 | $62.34 | 1.1M |
| Sep 22, 2026 | $66.24 | $66.58 | $65.36 | $65.96 | 1.31M |
| Sep 21, 2026 | $65.93 | $66.21 | $64.99 | $65.26 | 1.09M |
| Sep 18, 2026 | $68.00 | $68.005 | $65.18 | $65.37 | 3.86M |
| Sep 17, 2026 | $68.84 | $68.84 | $67.22 | $68.00 | 1.12M |
The latest Smart Investors Daily articles mentioning PTCT.
Company
Market Activity
Research & News
PTCT research
Company profile and research snapshot.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
| Sep 22, 2026 | Cantor Fitzgerald | Overweight | — |
| Aug 14, 2026 | Barclays | Overweight | — |
| Aug 13, 2026 | Wells Fargo | Overweight | — |
| Jul 31, 2026 | Morgan Stanley | Overweight | — |
No generated briefing is available yet.
Benzinga · Oct 8, 2026
RBC Capital analyst Brian Abrahams maintains PTC Therapeutics (NASDAQ:PTCT) with a Sector Perform and lowers the price target from $85 to $75.
Yahoo · Oct 6, 2026
Schneider Electric has agreed to buy PTC (PTC), an industrial software maker, and the stock rose 37.6% over the past five sessions against the S&P 500's 1.2%. After a move like that, holders may look again at what PTC does to the rest of their money, most of which probably follows the market. When the market has a bad day, does PTC make it worse for you.
Yahoo · Sep 30, 2026
PTC (PTC) and Fair Isaac are both owned for software that customers find hard to replace. PTC sells more to manufacturers it already serves, while Fair Isaac has raised the price of its mortgage credit score. Fair Isaac stock has lost 46% in a month, while PTC stock has lost 12.5%. Which of the two is gaining the firmer grip on its customers.
Yahoo · Sep 28, 2026
Leading CIOs and CISOs honored for leadership, innovation, and business impact at the Philadelphia ORBIE Awards on September 25, 2026 at Philadelphia Marriott Downtown. PHILADELPHIA, Sept. 28, 2026 (GLOBE NEWSWIRE) -- The 2026 Philadelphia ORBIE Awards honored leading chief information officers (CIOs) and chief information security officers (CISOs) from CSL Behring, PTC Therapeutics, The School District of Philadelphia, Riggs Distler, OceanFirst Bank, Trinseo, Children's Hospital of Philadelphia
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PTCT.
